Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
Company to expand robust Enterprise Imaging offering with addition of Inspirata’s Digital Pathology technology and team
December 19, 2022
This news release is issued by FUJIFILM Corporation in Japan.
Fujifilm makes no representation that products on this news release are commercially available in all countries and regions including the US and EU.
Approved uses of healthcare products vary by country and region.
Specifications and appearance of products are subject to change without notice.
TOKYO, December 20, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the company has entered into an asset purchase agreement to acquire the global digital pathology business of Tampa, Florida-based Inspirata, Inc. Upon completion of this agreement, Inspirata's Dynamyx® digital pathology technology, employees and customers will become part of Fujifilm. The addition of digital pathology will expand Fujifilm’s robust Synapse® Enterprise Imaging offering to enable the integration of pathology images and data into a healthcare organization’s electronic health record system and help to streamline care delivery for oncology patients and provider teams.
Building off the success of its established partnership with Inspirata, this acquisition marks Fujifilm’s full-scale, global entry into the largely unpenetrated digital pathology market, where 85% of U.S., 86% of European, and 90% of Asian healthcare organizations are still running on analog.
“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” says Teiichi Goto, president and CEO, representative director, FUJIFILM Corporation. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”
Dynamyx is an open, vendor-agnostic, end-to-end digital pathology solution. Dynamyx’s software capabilities include using whole slide images from multiple scanning vendors to create an easier path for more pathology labs to digitize and realize the benefits of faster patient results, centralized imaging records, and enterprise access to images for all clinicians. It is installed in medical facilities that handle large volumes of pathological images across multiple lab locations, allowing the use of their preferred mix of laboratory and diagnostic technologies with confidence of full compatibility. According to a recent DeciBio article, Dynamyx is shown to have one of the largest partnership networks in the digital pathology space.
It will become part of Fujifilm’s Synapse Enterprise Imaging portfolio – an award-winning suite of healthcare IT solutions that unify imaging, data access and workflows across the health system. With the addition of digital pathology, Fujifilm will offer one of the most comprehensive enterprise imaging portfolios on the market consisting of a Best in KLAS winning VNA, Radiology PACS, and Cardiology PACS, as well as an enterprise information system, cloud services, and 3D advanced visualization. Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development.
“A $320 million global industry in 2021 projected to reach $640 million*1 by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” says Henry Izawa, president and CEO, FUJIFILM Healthcare Americas Corporation. “These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the UK,” says Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president FUJIFILM Medical Systems Europe. “We've received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”
Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. With a specialty as image and data heavy as pathology, digitization is key. Pathologists, clinicians, patients, researchers and biopharma companies alike may see benefits such as improved and more efficient workflows, enhanced collaboration, remote and centralized interpretation, faster patient results, overall cost savings, ROI, and increased precision of diagnosis. Fujifilm’s existing partnership with Inspirata has demonstrated success in implementing these benefits for several global healthcare organizations.
Dynamyx has been cleared and/or approved for use in the U.S., Canada, Europe and the UK by each region’s regulatory agency. Dynamyx technology ownership and ongoing development and engineering will be led in the U.S. by FUJIFILM Healthcare Americas Corporation and licensed to other regions. Timing for the completion of the transaction is subject to closing conditions and is scheduled for early 2023. Terms of the agreement have not been disclosed.